Cargando…

Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells

We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bobardt, Michael, Chatterji, Udayan, Lim, Precious, Gawlik, Katarzyna, Gallay, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009744/ https://www.ncbi.nlm.nih.gov/pubmed/24799968 http://dx.doi.org/10.2174/1874357901408010001

Ejemplares similares

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175
por: Gallay, Philippe A., et al.
Publicado: (2016)

Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection
por: Chatterji, Udayan, et al.
Publicado: (2016)

HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex Formation
por: Gawlik, Katarzyna, et al.
Publicado: (2014)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
por: Stauffer, Winston, et al.
Publicado: (2023)

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015)

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019)

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
por: Kuo, Joseph, et al.
Publicado: (2019)

Alisporivir Inhibition of Hepatocyte Cyclophilins Reduces HBV Replication and Hepatitis B Surface Antigen Production
por: Phillips, Sandra, et al.
Publicado: (2015)

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance
por: Bobardt, Michael, et al.
Publicado: (2021)

Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection
por: Hansson, Magnus Joakim, et al.
Publicado: (2015)

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
por: Coelmont, Lotte, et al.
Publicado: (2010)

The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice
por: Bobardt, Michael, et al.
Publicado: (2020)

The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication
por: Foster, R.T., et al.
Publicado: (2017)

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate
por: Bobardt, Michael, et al.
Publicado: (2019)

Hepatitis C virus exploits cyclophilin A to evade PKR
por: Colpitts, Che C, et al.
Publicado: (2020)

Cyclophilin inhibitors as antiviral agents
por: Peel, Michael, et al.
Publicado: (2013)

Cyclophilin Inhibitors as a Novel HCV Therapy
por: Tang, Hengli
Publicado: (2010)

Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture
por: de Wilde, Adriaan H., et al.
Publicado: (2018)

Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
por: Lin, Kai, et al.
Publicado: (2013)

Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection
por: Hopkins, Sam, et al.
Publicado: (2012)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

An Antiviral Response Directed by PKR Phosphorylation of the RNA Helicase A
por: Sadler, Anthony J., et al.
Publicado: (2009)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Characterization of a ranavirus inhibitor of the antiviral protein kinase PKR
por: Rothenburg, Stefan, et al.
Publicado: (2011)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
por: Bobardt, Michael, et al.
Publicado: (2020)

Activation of the Antiviral Kinase PKR and Viral Countermeasures
por: Dauber, Bianca, et al.
Publicado: (2009)

Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents
por: Han, Jinhe, et al.
Publicado: (2022)

Genetic Barrier to Direct Acting Antivirals in HCV Sequences Deposited in the European Databank
por: Kliemann, Dimas Alexandre, et al.
Publicado: (2016)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
por: Fabrizi, Fabrizio, et al.
Publicado: (2019)

Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pnafn3vtkotjnoel3cf7ejui4l